Basic Research in Cardiology

, Volume 68, Issue 3, pp 318–334 | Cite as

Cardiac histological and serum-biochemical changes produced by various adrenergic stimulant drugs in the rat

  • E. Marmo
  • A. P. Caputi
  • R. K. Saini
Article

Summary

  1. 1.

    The rats given isoprenaline (1–10–100 mg/kg/die/4 days i.m.) showed myocardial infarctions on histological examination as well as increase in the levels of S-GOT, S-GPT and S-LDH.

     
  2. 2.

    The rats treated with various adrenergic β-stimulant drugs (terbutaline, salbutamol, soterenol, isoxsuprine, chlorprenaline, metaproterenol, ISOTIOD and quinterenol; 1–10–100 mg/kg/die/4 days i.m.) neither exhibited any significant cardiac histological changes (except infiltrations by histiocytes lymphocytes and monocytes with quinterenol and Th 1165a at 100 mg/kg/die/4 days i.m.) nor any changes in the levels of S-GOT and S-GPT.

     
  3. 3.

    At a dose of 100 mg/kg/die/4 days i.m. of the various β-stimulant drugs, a significant increase in the levels of S-LDH was observed in the rats.

     

Keywords

Public Health Myocardial Infarction Histological Examination Salbutamol Histological Change 

Riassunto

  1. 1.

    Un trattamento con isoprenalina (1–10–100 mg/kg/die/4 gg. i.m.) determina nel ratto lesioni cardiache infartosimili e aumento della S-GOT, della S-GPT e della S-LDH.

     
  2. 2.

    Un trattamento (1–10–100 mg/kg/die/4 gg i.m.) con varie sostance β-adrenergiche stimolanti (terbutalina, salbutamolo, soterenolo, Th 1165a, isoxsuprina, chlorprenalina, metaproterenolo, ISOTIOD, quinterenolo) non determina nel ratto significative modificazioni della istologia del miocardio (ad eccezione di circoscritti infiltrati istio-linfomonocitari nel miocardio di ratti trattati con 100 mg/kg/die/4 gg. i.m. di Th 1165a e di quinterenolo) e della S-GOT e della S-GPT.

     
  3. 3.

    Un trattamento (100 mg/kg/die/4 gg. i.m.) con varie sostanze β-adrenergiche stimolanti determina nel ratto un significativo aumento della S-LDH.

     

Zusammenfassung

  1. 1.

    Die Gabe von Isoprenalin (1–10–100 mg/kg/die für 4 Tage, im.) verusachi bei der Ratte histologsich infarktähnliche Myokardveränderungen und Erhöhung der S-GOT, der S-GPT und der S-LDH.

     
  2. 2.

    Eine Behandlung mit verschiedenen β-adrenergisch stimulierenden Substanzen (Terbutalin, Salbutamol, Soterenol, Th 1165a, Isoxsuprin, Chlorprenalin, Metaproterenol, ISOTIOD, Quinterenol; 1–10–100 mg/kg/die für 4 Tage i.m.) verursacht an der Ratte keine bedeutenden Veränderungen der Histologie des Myokards (mit Ausnahme von begrenzten histio-lymphomonozytären Infiltrationen im Myokard von Ratten, die mit 100 mg/kg/die für 4 Tage i.m. Quinterenol und Th 1165 a behandelt wurden), der S-GOT und der S-GPT.

     
  3. 3.

    Eine Behandlung (100 mg/kg/die für 4 Tage, i.m.) mit verschiedenen β-adrenergisch stimulierenden Substanzen, verursacht an der Ratte eine bedeutende Erhöhung der S-LDH.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Amelin, A. Z., I. Anshelevick andM. Melzobs, Experimental infactlike changes of the myocardium under the influence of isadrine (isopropylnoradrenaline). Arch. Path.25, 25–29 (1963).Google Scholar
  2. 2.
    Anichkov, S. V. andZ. I. Vedeneeva, Irritation of the sympathetic nerve as a cause of myocardial lesions. Acta Physiol.19, 17–18 (1961).Google Scholar
  3. 3.
    Arora, R. B., Mechanism of action of monoamine oxidase inhibitors in experimental myocardial infarction in the pig. Ann. N. Y. Acad. Sci.107, 1152–1158 (1963).Google Scholar
  4. 4.
    Arrigoni, E., Azione di un nitroderivato sulle lesioni miocardiche da isoproterenolo nel ratto. Il Farmaco (Ed. Pratica)24, 267–271 (1969).Google Scholar
  5. 5.
    Bajusz, E., J. R. Baker andC. W. Nixon, Effects of catecholamines upon cardiac and skeletal muscles of dystrophic hamsters. Fed. Proc.25, 475 (1966).Google Scholar
  6. 6.
    Bajuzs, E. andG. Jasmin, Protective action of serotonin against certain chemically and surgically induced cardiac necroses. Rev. canad. Biol.21, 51–52 (1962).PubMedGoogle Scholar
  7. 7.
    Bajusz, E. andG. Jasmin, Comparative morphogenesis and enzyme histogenesis of some occlusive and metabolic cardiac necroses. Rev. canad. Biol.22, 181–199 (1963).PubMedGoogle Scholar
  8. 8.
    Bajusz, E. andG. Jasmin, Enzyme histochemistry of some chemically induced cardiac necroses. II. Myocardial lesions induced by methoxamine. Z. Vitamin-, Hormon-und Fermentforschg.14, 43–56 (1965).Google Scholar
  9. 9.
    Bajusz, E. andG. Jasmin, Influence of variations in electrolyte intake upon the development of cardiac necrosis produced by vasopressor amines. Lab. Invest.13, 757–766 (1966).Google Scholar
  10. 10.
    Balazs, T., J. B. Murphy andH. C. Grice, The influence of environmental changes on the cardiotoxicity of isoproterenol in rats. J. Pharm. Pharmacol.14, 750–955 (1962).PubMedGoogle Scholar
  11. 11.
    Balazs, T., M. R. Sahasrabudhe andH. C. Grice, The influence of excess body fat on the cardiotoxicity of isoproterenol in rats. Toxicol. appl. Pharmacol.4, 613–620 (1962).Google Scholar
  12. 12.
    Breining, H. undO. Strubelt, Die Bedeutung der adrenergischen β-Rezeptoren für die cardiotoxische Wirkung sympathicomimetischer Amine. Med. Pharmacol. exp.13, 169–176 (1965).Google Scholar
  13. 13.
    Brown, M. L. andJ. J. McGrath, Thiamine deficiency and experimental cardiac necrosis. Proc. Soc. Exp. Biol. (N.Y.)135, 735–738 (1970).Google Scholar
  14. 14.
    Chappel, C. I., G. Rona, T. Balazs, andR. Gaudry, Severe myocardial necrosis by isoproterenol in the rat. Arch. int. Pharamcodyn.122, 123–128 (1959).Google Scholar
  15. 15.
    Chappel, C. I., G. Rona, T. Balasz, andR. Gaudry, Comparison of cardiotoxic actions of certains sympathomimetic amines. Canad. J. Biochem.37, 35–42 (1959).PubMedGoogle Scholar
  16. 16.
    Chappel, C. I., G. Rona, andR. Gaudry, The influence of adrenal cortical steroids on cardiac necrosis produced by isoproterenol. Acta endocr. (Kbh.)32, 419–424 (1959).Google Scholar
  17. 17.
    Chappel, C. I., G. Rona, andR. Gaudry, Relationship between adrenal cortex and the cardiotoxic properties of isoproterenol. International Symposium on the Catecholamines in Cardiovascular Pathology, Vermont (1959).Google Scholar
  18. 18.
    Chappel, C. I., R. Rona, andR. Gaudry, Relationship between thyroid function and cardiotoxic properties of isoproterenol. Endocrinology65, 208–215 (1959).PubMedGoogle Scholar
  19. 19.
    Classen, H.G., B. Solymoss, andS. Varga, Aggravation of adrenergic cardiopathy by cyclohexylamine. Arzneimittel-Forschg.19, 1805–1807 (1959).Google Scholar
  20. 20.
    Classen, H. G., B. Solymoss andS. Varga, Influence of cyclohexylamine on the adrenergic cardiopathy. Canad. J. Physiol.48, 226–231 (1970).Google Scholar
  21. 21.
    Clementi, F., J. Nidiry, andC. Peracchia, Ultrastructural observations of infarct-like lesions induced by isoproterenol. In: Editor:M. Tilbach, Electron Microscopy, Vol. B,, pp. 103–104 (Prague 1959).Google Scholar
  22. 22.
    Cox, G. E. andB. C. Wexler, Platelet and fibrin thrombi in isoproterenol-induced myocardial necrosis. Fed. Proc.27, 413 (1968).Google Scholar
  23. 23.
    D'Amato, L., Sulle alterazioni prodotte dagli estratti di capsule surrenali nei vasi sanguigni e in altri organi. G. int. Sci. med.27, 746–748 (1905).Google Scholar
  24. 24.
    D'Amato, L., Weitere Untersuchungen über die von den Nebennierenextrakten bewirkten Veränderungen der Blutgefäße und anderer Organe. Berl. Klin. Wschr. 1100–1102, 1131–1134 (1906).Google Scholar
  25. 25.
    Danilova, K. M.: On the nature of experimental adrenal myocarditis. Arkh. Pat. No. 11, 11–18 (1961).Google Scholar
  26. 26.
    Dertinger, B. L., D. C. Beaver, andA. H. Lands, Toxicity of 1-(3,4-dihydroxyphenil)-2-Isopropilaminoethanol hydrochloride (Isuprel). Proc. Soc. Exp. Biol. (N.Y.)68, 501–505 (1948).Google Scholar
  27. 27.
    Djordjevic, B. S., Z. Jgnjacev, M. Sindjjc etI. Stojanovic, Études expérimentales sur la noradrenaline. Concours méd.86, 1171–1180 (1964).Google Scholar
  28. 28.
    Dorigotti, L., M. Gaetani, A. H. Classer, andE. Turolla, Competitive antagonism of isoprenaline-induced cardiac necrosis by β-adrenoreceptor blocking agents. J. Pharm. Pharmacol.21, 188–191 (1969).PubMedGoogle Scholar
  29. 29.
    Ehringer, H. undH. Goegel, Zur Wirkung von Nethalide auf eine experimentelle ausgelöste Myocardnekrose. Arch. exp. Path. Pharmak.246, 47–48 (1963).Google Scholar
  30. 30.
    Eichbaum, F. W. andS. Zyngier, Inhibition of adrenergic cardiopathies by drugs: Dicumarol and Persantine. Comm. IV Int. Congr. Pharm. Basel, July 14–18 p. 160 (1969).Google Scholar
  31. 31.
    Eichbaum, F. W., S. Zyngier, andE. Pimenta de Campos, Inhibition of adrenergic cardiopathies by drugs. I: Dipyridamole. Arch. Kreislaufforschg.62, 56–64 (1970).Google Scholar
  32. 32.
    Eichbaum, F. W. andS. Zyngier, Inhibition of adrenergic cardiopathies by drugs. II: Anticoagulants. Arch. Kreislaufforschg.62, 65–71 (1970).Google Scholar
  33. 33.
    Enger, R., Die Wirkung langfristiger Adrenalin-Injektionen auf den Hund. Z. ges. exp. Med.108, 300–316 (1940).Google Scholar
  34. 34.
    Ferrans, V. J., R. G. Hibbs, W. C. Black, andD. G. Weilbächer, Isoproterenol-induced myocardial necrosis. A histochemical electron microscopic study. Amer. Heart J.68, 71–90 (1964).PubMedGoogle Scholar
  35. 35.
    Ferrans, V. J., R. G. Hibbs, J. J. Walsh, andG. E. Burch, Histochemical and electron microscopical studies on the cardiac necrosis produced by sympatomimetic agents. Ann. N.Y. Acad. Sci.156, 303–309 (1969).Google Scholar
  36. 36.
    Fleisher, M. S. undL. Loeb, Uber experimentelle Myocarditis. Zbl. allg. Path. Anat.20, 104–106 (1909).Google Scholar
  37. 37.
    Fleckenstein, A., H. J. Döring, andO. Leder, The significance of high-energy phosphate exhaustion in the etiology of isoproterenol-induced cardiac necrosis and its prevention by iproveratril, compound D 600 or prenylamine. In: Médicaments et métabolisme du myocarde et du muscle strié. Symp. Nancy, p. 11–22 (1969).Google Scholar
  38. 38.
    Fleckenstein, A., Die Zügelung des Myocardstoffwechsels durch Verapamil. Angriffspunkte und Anwendungsmöglickeiten. Arzenimittelforschg.20, 1317–1323 (1970).Google Scholar
  39. 39.
    Gabbiani, G., B. Tuchweber, G. Côte, U. S. Pahk, andH. Selye, Influence of thyroparathyroid apparatus on experimental soft-tissue carcification. Excerpta med. Int. Congr. Ser. n.159, 485–498 (1969).Google Scholar
  40. 40.
    Gábor, G., Z. Szabó, G. Erdélyi, I. Jugasz undJ. Szinnay, Die Wirkung eines eiweißfreien Herzmuskelextraktes auf experimentelle Myocardnekrose und Rhythmusstörungen. Med. exp.4, 261–267 (1961).PubMedGoogle Scholar
  41. 41.
    Gans, J. G. andM. R. Cater, Norepinephrine induced cardiac hypertrophy in dogs. Life Sci.9, 731–740 (1970).Google Scholar
  42. 42.
    Gompertz, C., Über Herz und Blutkreislauf beim nackten Amphibien. Arch. Anat. Physiol. 242–269 (1884).Google Scholar
  43. 43.
    Grober, Massenverhältnisse des Herzens bei künstlicher Arterienstarre. Dtsch. med. Wschr.33, 744 (1907).Google Scholar
  44. 44.
    Gryglewski, R. J., A. Kulig, andE. Kostkatrabka, Myocardial necroses produced by intravenous infusion of isoprenaline into rats. J. Pharm. Pharmac.23, 926–930 (1971).Google Scholar
  45. 45.
    Halpern, B. N., J. C. Morard etC. Drudi-Baracco, Action protectrice de la réserpine sur les lésions de dégènérescence myocardique aigue provoquées par la DL-amphétamine et suppression de cette action par les inhibiteurs de la monomineoxidase. C. R. Soc. Biol. 156, 773–779 (1962).Google Scholar
  46. 46.
    Handforth, C. P., Isoproterenol-induced myocardial infarction and necrotizing arteritis in hamsters, produced by isoproterenol (Isuprel). Med. Serv. J. Can.18, 506–512 (1962).PubMedGoogle Scholar
  47. 48.
    Hatt, P. Y., Ch. Ledoux etJ. P. Bonvalet, Lyse et synthèse de proteines myocardiques au cours de l'insuffusance cardiaque experimentale. Arch. Mal. Cœur58, 1703 (1965).Google Scholar
  48. 49.
    Herbertson, B. M. andT. D. Kellaway, Arterial necrosis in the rat produced by methoxamine. J. Path. Bact.80, 87–92 (1960).PubMedGoogle Scholar
  49. 50.
    Highman, B., Maling, H. M., andE. C. Thompson, Serum transaminase and alkaline phosphatase levels after large doses of norepinephrine and epinephrine in dogs. Amer. J. Physiol.196, 436–440 (1959).PubMedGoogle Scholar
  50. 51.
    Hill, R., A. N. Howard, andG. A. Greshman, The electrocardiographic appearances of myocardial infarction in the rat. Brit. J. exp. Path.41, 633–637 (1960).PubMedGoogle Scholar
  51. 52.
    Hiott, D. W., Ultrastructural changes in heart muscle after hemorrhagic shock and isoproterenol infusions. Arch. int. Pharmacodyn.180, 206–216 (1969).PubMedGoogle Scholar
  52. 53.
    Hoak, J. C., E. D. Warner, andW. E. Connor, New concept of levarterenol-induced acute myocardial necrosis. Arch. Path.87, 332–338 (1969).PubMedGoogle Scholar
  53. 54.
    Jasmin, G., Factors influencing the production of cardiomyopathies by methoxamine and metaraminol. Ann. N. Y. Acad. Sci.156, 333–343 (1969).PubMedGoogle Scholar
  54. 55.
    Jasmin, G. etE. Bajusz, Étude pathogénique des lésions cardiaques rénales et musculaires provoquées chez le par la méthoxamine et le métaraminol. Rev. Canad. Biol.23, 67–76 (1964).PubMedGoogle Scholar
  55. 56.
    Jelínková, M. andM. Smrz, LDH Isoenzyme spectrum in the myocardium of rats after repeated doses of isoproterenol. Experentia26, 504–505 (1970).Google Scholar
  56. 57.
    Judd, J. T. andB. C. Wexler, Acute changes in liver lipids during myocardial infarction induced by isoproterenol. Proc. Soc. exp. Biol. (N.Y.)130, 1302–1305 (1969).Google Scholar
  57. 58.
    Kahn, D. S., G. Rona, andC. I. Chappel, Isoproterenol-induced cardiac necrosis. Ann. N.Y. Acad. Sci.156, 285–293 (1969).PubMedGoogle Scholar
  58. 59.
    Kako, K., Biochemical changes of the rat myocardium induced by isoproterenol. Canad. J. Physiol. Pharmacol.43, 541–549 (1965).Google Scholar
  59. 60.
    Kaufman, N., T. L. Gavan, andR. W. Hill, Experimental myocardial infarction in the rat. Arch. Path.67, 482–488 (1959).Google Scholar
  60. 61.
    Kimura, H., E. Bajusz, H. C. Herrlich, andW. Raab, Pre-necrotic epinephrine and corticoid-induced myocardial electrolyte shifts. Cardiologia53, 175–191 (1968).Google Scholar
  61. 62.
    Kolbel, F., J. Kapitola etJ. Dvorak, Thyroidine plus isopropylnoradrenaline-induced cardiac hypertrophy. In: Médicaments et métabolisme du myocarde et du muscle strié. Symp. int. Nancy, p. 125–130 (1969).Google Scholar
  62. 63.
    Kolbel, F., W. F. H. M. Mommaerts, andV. Kolblova, Ribosomes of the heart muscle in the early phase of the development of experimental cardiac hypertrophy. Sbornik lék.70, 142–147 (1968).Google Scholar
  63. 64.
    Korb, G., Elektronenmikroskopische Befunde am Herzmuskel nach hohen Aludrinonjektionen. Verh. dtsch. Ges. Path.48, 245–250 (Stuttgart 1964).Google Scholar
  64. 65.
    Korb, G., Elektronenmikroskopische Untersuchungen zur Aludrin (Isoproterenolsulfat) Schädigung des Herzmuskels. Virchows Arch. path. Anat.339, 136–150 (1965).Google Scholar
  65. 66.
    Laudahn, G., Die Wirkung von Persantin auf Herzmuskelsarkosomen. Experientia17, 415–416 (1961).PubMedGoogle Scholar
  66. 67.
    Kupnovitskaya, I. G., Novocain action on the course of experimental isopropyl arterenol-induced necroses of the myocardium. Farmacology y Toxicology n. 3, 295–297 (1970).Google Scholar
  67. 68.
    Lehr, D., Tissue electrolyte alteration in disseminated myocardial necrosis. Ann. N.Y. Acad. Sci.156, 344–378 (1969).PubMedGoogle Scholar
  68. 69.
    Lehr, D., M. Krukowski, andR. Chau, Acute myocardial injury produced by sympathominetic amines. Israel. J. med. Sci.5, 519–524 (1969).Google Scholar
  69. 70.
    Lehr, D., M. Krukowski, andR. Colon, Correlation of myocardial and renal necrosis with tissue electrolyte changes. J. Amer. med. Ass.197, 105 (1966).Google Scholar
  70. 71.
    Leszkovsky, G. P. andG. Gal, Observations on isoprenaline-induced myocardial necrosis. J. Pharm. Pharmacol.19, 226–230 (1967).PubMedGoogle Scholar
  71. 72.
    Leszkovsky, G. P., G. Gal, andL. Tardos, Correlation between functional and morphological heart changes due to isoproterenol. Experientia23, 112–113 (1967).PubMedGoogle Scholar
  72. 73.
    Loeper, J. etJ. Loeper, Recherches sur le rôle du silicium dans la paroi artérielle. C. R. Soc. Biol.155, 468–470 (1961).Google Scholar
  73. 74.
    Mainardi, G. C., Contributo alla conoscenza delle modificazioni isto-morfologiche polmonari e cardiache sperimentalmente indotte in cavie trattate con isoproterenolo. Boll. Soc. med. chir. Pisa35, 249–258 (1968).Google Scholar
  74. 75.
    Maling, H. M. andB. Highman, Exagerated ventricular arrhythmias and myocardial fatty changes after doses of norepinephrine and epinephrine in unanesthetized dogs. Amer. J. Physiol.194, 590–596 (1958).PubMedGoogle Scholar
  75. 76.
    Maling, H. M., B. Highman, andE. C. Thompson, Some simular effects after large doses of catecholamines and myocardial infarction in dogs. Amer. J. Cardiol.5, 628–633 (1960).PubMedGoogle Scholar
  76. 77.
    Marmo, E., Effetti della terbutalina sull'apparato cardiovascolare e sulle muscolature tracheobronchiale, gastro-intestinale, splencia e deferenziale. Ricerche sperimentali comparative con isoprenalina, metaproterenolo, soterenolo, salbutamolo, clorprenalina, isossisuprina e quinterenolo. Il Farmaco (Ed. Pratica)26, 426–497 (1972).Google Scholar
  77. 78.
    Marmo, E.: Effects of various drugs on the cardiac changes by isoprenaline. Proc. Europ. Soc. for the Study Toxicity. The correlation of adverse effects in man with observations in animals. Ed. Excerpta Medica.12, 160–178 (1971).Google Scholar
  78. 79.
    Marmo, E. andA. P. Caputi, Analysis of the adrenergic effects of various drugs. Arch. int. Pharmacodyn. (In press 1972).Google Scholar
  79. 80.
    Marmo, E. eA. P. Capuli, Aspetti farmacodinamici di un nuovo coronariodilatatori: il maleato di (3, 4, 5, trimetossicinnamoil)-1 (acetato di etile)-4-piperazina (6753). Boll. Soc. Ital. Cardiol.16, 523–530 (1971).PubMedGoogle Scholar
  80. 81.
    Marmo, E., E. P. Caputi, R. K. Saini, andO. Ortolani, On the pharmacology of the 1-(4′-oxyplenyl)-2-(3′-phenyl-tio-propyl-amino)-propane-1-olo chlorhydrate (ISOTOID). Comm. VIII Int. Congress of angiology, Rio de Janeiro 24–30 July 1972.Google Scholar
  81. 82.
    Maruffo, C. A., Fine structural study of myocardial changes induced by isoproterenol in rhesus monkeys (Macaca mulatta). Amer. J. Path.50, 27–35 (1967).PubMedGoogle Scholar
  82. 83.
    Mattioli, M., Su due casi di infarto del miocardio in seguito ad endovenosa di ardenalina. Progr. med. (Napoli)4, 266–268 (1948).Google Scholar
  83. 84.
    Mc Grath, J. J. andM. L. Brown, Time course of resistance to experimental cardiac necrosis in thiamine-deficient rats. Proc. Soc. Exp. Biol. (N.Y.)138, 1075–1077 (1971).Google Scholar
  84. 85.
    Méhes, G., G. Papp, andK. Rajkovits, Effect of adrenergic α- and β-receptor blocking drugs on the myocardial lesions induced by sympathomimetic amines. Acta physiol. Acad. Sci. hung.32, 175–184 (1967).PubMedGoogle Scholar
  85. 86.
    Méhes, J., K. Rajkovits, andJ. Papp, Effect of various types of sympatholytics of isoproterenol-induced myocardial lesions. Acta physiol. Acad. Sci. hung.29, 75–85 (1966).PubMedGoogle Scholar
  86. 87.
    Mehrotra, R. M. L. andH. M. Sharma, Cardiac injury following administration of isoprenaline. An experimental study. Indian J. med. Sci.21, 395–400 (1967).PubMedGoogle Scholar
  87. 88.
    Meltzer, H. Y. andA. Guschwan, Effect of isoproterenol on rat plasma creatine phosphokinase activity. Arch. int. Pharmacodyn.194, 141–146 (1971).PubMedGoogle Scholar
  88. 89.
    Moravec, J. andP. Y. Hatt, Effects of Isuprel on the myocardium electron microscopic analysis. In: Médicaments et Métabolisme du myocarde et du muscle strié. Symp. int. Nancy p. 85–92 (1969).Google Scholar
  89. 90.
    Moravec, J. etP. Y. Hatt, Necrose myocardique experimentale provoquée par l'isopropylnoradrenaline. Pathol. Biol.17, 585 (1969).PubMedGoogle Scholar
  90. 91.
    Mortari, A., F. Piccinini eG. Sioli, Sull'infarto miocardico sperimentale da isoproterenolo nei piccoli animali: Studio elettrocardiografico. Mal. cardiovasc.4, 689–707 (1963).Google Scholar
  91. 92.
    Moudgil, L. R., Possible protective action of antialdosterone compounds in myocardial necrosis in rats. Brit. J. Pharmac.35, 558–562 (1969).Google Scholar
  92. 93.
    Müller, E., Histochemical studies on the experimental heart infarction in the rat. Naunyn-Schmiedebergs Arch. exp. Path. Pharmak.254, 439–447 (1966).Google Scholar
  93. 94.
    Nahas, G. G., W. C. Manion etJ. C. Brunson, Lésions cardiaques per excès de norépinéphrine. Presse méd.67, 1079–1082 (1959).Google Scholar
  94. 95.
    Niles, N. R., J. D. Zavin andR. N. Moricado, Histochemical study of effects of hypoxia and isoproterenol on rat myocardium. Amer. J. Cardiol.22, 381–388 (1968).PubMedGoogle Scholar
  95. 96.
    Ostádal, B. andO. Poupa, Occlusion of coronary vessels after administration of isoprenaline, adrenaline and noradrenaline. Physiol. bohemoslov.16, 116–119 (1967).Google Scholar
  96. 97.
    Ostádal, B., V. Rychterova, andO. Poupa, Isoproterenolidnuced acute experimental cardiac necrosis in the turtle (Testudo Horsfieldi). Amer. Heart. J.76, 645–649 (1968).PubMedGoogle Scholar
  97. 98.
    Ostádal, B. andO. Poupa, Occlusion of coronary vessles after administration of isoprenaline, adrenaline and noradrenaline. Physiol. Bochemoslav.16, 116–119 (1967).Google Scholar
  98. 99.
    Ostádal, B., V. Tychterova, andO. Poupa, Isoproterenol-induced acute experimental cardiac necrosis in the turtle (Testudo Horsfieldi). Amer. Heart J.76, 645–649 (1968).PubMedGoogle Scholar
  99. 100.
    Pearce, R. M., Experimental myocarditis; a study of the histological changes following intravenous injections of adrenaline. J. exp. Med.8, 400–409 (1906).Google Scholar
  100. 101.
    Pilny, J., G. Kiefer undW. Sandbritter, Quantitative und qualitative polarisationsoptische Untersuchungen am Myosin des Rattenherzens. Virchows Arch. Abt B. Zelpath.3, 359–364 (1969).Google Scholar
  101. 102.
    Poupa, O. andA. Carlsten, Comparative aspect to poikilotherms In: Médicaments et métabolisme du myocarde et du muscle strié. Symp. Int. Nancy p. 55–75 (1969).Google Scholar
  102. 103.
    Poupa, A., K. Krofta, J. prochazka, andZ. Turek, Acclimation to simulated highaltitude and acute cardiac necrosis. Fed. Proc.25, 1243–1246 (1966).PubMedGoogle Scholar
  103. 104.
    Poupa, O. andB. Ostádal, Experimental cardiomegalies and “cardiomegalies” in free-living animals. Ann. N.Y. Acad. sci.156, 445–468 (1969).PubMedGoogle Scholar
  104. 105.
    Poupa, O., Z. Turek, M. Kaluz, andK. Kroffa, Acute cardiac infarct-like necrosis in high-altitude adapted rats. Physiol. bohemoslov.14, 542–545 (1965).PubMedGoogle Scholar
  105. 106.
    Poynter, D. andN. W. Spurling, Some effects of beta-adrenergic stimulants in animals. Postgrad. Med. J.,47 (suppl.) 21–25 (1971).Google Scholar
  106. 107.
    Preti, M., G. Abbondati, andC. Carpi, Attività protettiva di una forma ritardo della trinitroglicerina sull'infarto sperimentale da isoproterenolo nel ratto. Boll. chim. farm.108, 576–580 (1969).PubMedGoogle Scholar
  107. 108.
    Raab, W., E. Stark, W. H. MacMillan, andW. R. Gigee, Sympathogenic origin and antiadrenergic prevention of stress-induced myocardial lesions. Amer. J. Cardiol.8, 203–211 (1961).PubMedGoogle Scholar
  108. 109.
    Rakusan, K., H. Tietzova, Z. Turek, andO. Poupa, Cardiomegaly after repeated application of isoprenaline in the rat. Physiol. bohemoslov.14, 456 (1965).PubMedGoogle Scholar
  109. 110.
    Reitman, S. andS. Frankel, Amer. J. Clin. Path.28, 56 (1957). In:Karlson, Biochimica (Milano 1971).Google Scholar
  110. 111.
    Rona, G., In: Animal and Clinical Pharmacologic Techniques in Drug Evaluation, Vol. II p. 464. Editors:P. E. Siegler andJ. H. Moyer. (Chicago, III 1967).Google Scholar
  111. 112.
    Rona, G., C. I. Chappel, T. Balazs andR. Gaudry, An infarct-like myocardial lesion and other toxic manifestations produced by isoproterenol in the rat. Arch. Path.67, 443–445 (1959).Google Scholar
  112. 113.
    Rona, G., C. J. Chappel, T. Balazs, andR. Gaudry, The effect of breed, age and sex on myocardial necrosis produced by isoproterenol in the rat. J. Geront14, 169–173 (1959).PubMedGoogle Scholar
  113. 114.
    Rona, G., C. I. Chappel, T. Balazs, andR. Gaudry, Severe myocardial necrosis produced by isoprotenrenol in the rat. Arch. int. Pharmacodyn.122, 123–128 (1959).PubMedGoogle Scholar
  114. 115.
    Rona, G., C. I. Chappel, andR. Gaudry, Effect of dietary sodium and potassium content on myocardial necrosis elicited by isoproterenol. Lab. Invest.10, 892–897 (1961).Google Scholar
  115. 116.
    Rona, G., C. I. Chappel, andD. S. Kahn. The significance of factors modifying the development of isoproterenol-induced myocardial necrosis. Amer. Heart J.66, 389–395 (1963).PubMedGoogle Scholar
  116. 117.
    Rona, G., C. I. Chappel, andD. S. Kahn, Experimental production of chronic cardiac aneurism and congestive heart failure in the rat. Exp. molec. Path.2, 40–51 (1963).PubMedGoogle Scholar
  117. 118.
    Rona, G., D. S. Kahn, andC. J. Chappel, Pathology and pathogenesis of experimental infarction. Proc. of 59th Annual Meeting of the American Association of Pathologists and Bacteriologists, p. 23 (1962).Google Scholar
  118. 119.
    Rona, G., D. S. Kahn, andC. I. Chappel, Studies on infarct-like myocardial necrosis produced by isoproterenol: a review. Rev. canad. Biol.22, 241–255 (1963).PubMedGoogle Scholar
  119. 120.
    Rona, G., T. Zsoter, C. I. Chappel, andR. Caudry, Myocardial lesions, circulatory and electrocardiography changes produced by isoproterenol in the dog. Rev. canad. Biol.18, 83–94 (1959).PubMedGoogle Scholar
  120. 121.
    Rona, G. andD. S. Kahn, Experimental studies on the healing of cardiac necrosis. Ann. N.Y. Acad. Sci.156, 177–188 (1969).PubMedGoogle Scholar
  121. 122.
    Rona, G., D. S. Kahn, andC. I. Chappel, Study on the healing of cardiac necrosis in the rat. Amer. J. Path.39, 473–489 (1961).PubMedGoogle Scholar
  122. 123.
    Rosenblum, I., A. Wohll, andA. a. Stein, Studies in cardiac necrosis. I. Production of cardiac lesions with sympathomimetic amines. Toxicol. appl. Pharmacol.7, 1–8 (1965).Google Scholar
  123. 124.
    Rosenblum, I., A. Wohl, andA. Stein, Studies in cardiac necrosis, II. Cardiovascular effects of sympathomimetic amines producing cardiac lesions. Toxicol. appl. Pharmacol.7, 9–17 (1965).Google Scholar
  124. 125.
    Rosenblum, I., A. Wohl, andA. A. Stein, Studies in cardiac necrosis. III. Metabolic effect of sympathomimetic amines producing cardiac lesions. Toxicol. appl. Pharmacol.7, 344–351 (1965).Google Scholar
  125. 126.
    Rosenmann, E., E. Gazenfield, A. Laufer, andA. M. Davies, Isoproterenol-induced myocardial lesions in the immunized and non immunized rat. Path. et Microbiol. (Basel)27, 303–309 (1964).Google Scholar
  126. 127.
    Samson, P. C., Tissue changes followin continous intravenous injection of epinephrine hydrochloride into dogs. Arch. Path.13, 745–755 (1992).Google Scholar
  127. 128.
    Schenk, E. A., Endogenous nor-epinephrine release and mycocardiopathy. Fed. Proc.22, 253 (1963).Google Scholar
  128. 129.
    Schenk, E. A. andA. J. Moss, Cardiovascular effect of sustained norepinephrine infusions. II. Morphology. Circulat. Res.18, 605–615 (1966).PubMedGoogle Scholar
  129. 130.
    Schirokogorow, J., adrenalinver. d. Arterien. Thesis, University of Dorpat (1907).Google Scholar
  130. 131.
    Schmidt, H., H. J. Bermann undK. Heckel, Elektrokardiographische und histologische Befunde bei Hypertonie durch Noradrenalin im Tierexperiment. Arch. Kreislaufforschg.36, 274–296 (1961).Google Scholar
  131. 132.
    Scribine, A. andR. B. Stebbins, Protection of rats from isoproterenol induced myocardial necrosis by trolnitrate phosphate (Metamine). Experientia22, 106–107 (1966).PubMedGoogle Scholar
  132. 133.
    Selye, H.: The Pluricausal Cardiopathies. (Springfield, III 1961).Google Scholar
  133. 134.
    Selye, H., Experimental cardiovascular disease. Ed. (Springer-Verlag Berlin/Heidelberg/New York 1970).Google Scholar
  134. 135.
    Selye, H., E. Bajuzs andR. Veilleux, Production of dissecting aneurysms by chronic isoproterenol treatment. Cor et Vasa (Praha),2, 273–275 (1960).Google Scholar
  135. 136.
    Sorokina, M. N. andR. A. Altshuler, Indrine-induced experimental necroses of the myocardium in albino rats. Farmakol. Toksikol.29, 362–365 (1966).Google Scholar
  136. 137.
    Souhrada, J. andR. W. Bullard, Tissue buffering capacity: its role in the prevention of isoproterenol induced necrosis. Life Sci.10, 559–564 (1971).Google Scholar
  137. 138.
    Stanton, H., Studies on isoproterenol- induced cardiac hypertrophy. Fed. Proc.26, 398 (1967).Google Scholar
  138. 139.
    Stanton, H. C., Isoproterenol cardiomegaly in rats. In: Médicantes et métabolisme du myocarde et du muscle strié. Symp. int. Nancy p. 23–27 (1969).Google Scholar
  139. 140.
    Stanton, H. C., G. Brenner, E. D. Mayfield, Studies on isoproterenol-induced cardiomegaly in rats. Amer. Heart J.77, 72–80 (1969).PubMedGoogle Scholar
  140. 141.
    Stanton, H. C., A. Schwartz, Effect of certain monoamine oxidase inhibitors on isoproterenol-induced cardiac necrosis in rats. Proc. West. Pharmacol. Soc.9, 6–8 (1966).PubMedGoogle Scholar
  141. 142.
    Stanton, H. C. andA. Schwartz, Effects of a hydrazine monoamine oxidase inhibitor (phenelzine) on isoproterenol-induced myocardiopathies in the rat. J. Pharm. exp. Ther.157, 649–658 (1967).Google Scholar
  142. 143.
    Stief, A. andL. Tokay, Further contributions to the histopathology of experimental adrenaline intoxication. J. nerv. ment. Dis.81, 633–648 (1935).Google Scholar
  143. 144.
    Strickler, A. andM. S. Fleischer, The influence of intravenous injections of sparteine and adrenalin on the heart of the dog. J. Pharm. exp. Ther.2, 55–57 (1910).Google Scholar
  144. 145.
    Strubelt, O. undH. Breining, Zur Pathogenese und pharmakologischen Beeinflussung der durch Isoprenalin-Vergiftung hervorgerufenen Myocardnekrosen. Arzneimittelforschg.14, 1196–1198 (1964).Google Scholar
  145. 146.
    Szakacs, J. E. andA. Cannon, 1-Norepinephrine myocarditis. Amer. J. clin. Path.30, 425–434 (1958).Google Scholar
  146. 147.
    Szakacs, J. E., R. M. Dimmette, E. C. Cowart Jr., R. J. Sandidge, andH. W. Sellers, Pathologic implication of the catecholamines: epinephrine and norepinephrine (Progr. Rep., Res. Project No. NM 71-01-21.3) Bethesda, Md.: U.S. Naval med. School. (1959).Google Scholar
  147. 148.
    Szakacs, J. E. andC. D. Fobes, 1-Norepinephrine. A pathologist's approach to recent investigations. Maryland St. med. J.9, 83–89 (1960).Google Scholar
  148. 149.
    Ssakacs, J. E. andB. Mehlman, Pathologic changes induced by 1-norepinephrine. Quantitative aspects. Amer. J. Cardiol.5, 619–627 (1960).PubMedGoogle Scholar
  149. 150.
    Turek, Z., J. Jelínek, M. Kaluš, andO. Poupa, Potassium, sodium and chlorides in the heart of rats with isoprenaline-induced experimental necrosis of the myocardium. Physiol. Bohemoslov.17, 48–54 (1968).PubMedGoogle Scholar
  150. 151.
    Turek, Z., M. Vizek, K. Rakusan, andO. Poupa, Cardiomegaly in rat after repeated administration of isoprenaline and thyroidine. Physiol. Bohemoslov.17, 43–47 (1968).PubMedGoogle Scholar
  151. 152.
    Veith, G., Experimentelle Untersuchungen zur Wirkung von Adrenalin auf den Herzmuskel. Arch. Kreislaufforschg.6, 335–360 (1940).Google Scholar
  152. 153.
    Vishnevskaia, O. P., Areaktivnost miokarda belykh krys k povtornym inektsiiam bolshikn dox adrenalina. Byull. eksp. Biol. Med.38, 29–32 (1954).Google Scholar
  153. 154.
    Vishnevskaia, O. P., Reflex mechanisms in the pathogenesis of adrenaline myocarditis. Bull. exp. Biol. Med.41, 307–310 (1956).Google Scholar
  154. 155.
    Vishnevskaia, O. P., The question of the reactivity oft he organism adrenaline. Change in the reactivity of the myocardium and epithelium of the cornea. In: Sovrem. vopr. nerv. fisiol. i patol. Sbornik nauchny. rabot, p. 241–252. (Moscow 1958).Google Scholar
  155. 156.
    Vishnewskaia, O. P. andN. A. Jushchenko Concerning the mechanism producing an adrenaline myocarditis. Bull. exp. Biol. Med.44, 932–936 (1957).Google Scholar
  156. 157.
    Zalis, E. G., G. D. Lundberg, andR. A. Knutson, The pathophysiology of acute amphetamine poisoning with pathologic correlation. J. Pharm. exp. Ther.158, 115–127 (1967).Google Scholar
  157. 158.
    Zbinden, G., Theoretic background of therapy with monoamine oxidase inhibitors in cardiology. Amer. J. Cardiol.6, 1121–1124 (1960).PubMedGoogle Scholar
  158. 159.
    Zbinden, G., Inhibition of experimental myocardial necrosis by the monoamine oxidase inhibitor isocarboxazid (Marplan). Amer. Heart J.60, 450–453 (1960).Google Scholar
  159. 160.
    Zbinden, G., Effect of anoxia and monoamine oxidase inhibitors on myocardial necrosis induced by isoproterenol. Fed. Proc.21, 128 (1961).Google Scholar
  160. 161.
    Zbinden, G., Beeinflussung der experimentellen, durch Isoproterenol hervorgerufenen Moycardnekrose durch Aminoxydasehemmer, gefäßerweiternde und tracquilisierende Arzneimittel. Arzneimittelforschg.12, 635–638 (1962).Google Scholar
  161. 162.
    Zbinden, G. andR. E. Bagdon, Isoproterenol-induced heart necrosis, an experimental model for the study of angina pectoris and myocardial infarct. Rev. canad. Biol.22, 257–263 (1963).PubMedGoogle Scholar
  162. 163.
    Zbinden, G. andR. A. Moe, Pharmacological studies on heart muscle lesions induced by isoproterenol. Ann. N. Y. Acad. Sci.156, 294–308 (1969).PubMedGoogle Scholar
  163. 164.
    Ziegler, K., Uber die Wirkung intravenöser Adrenalininjektion auf das Gefäßsystem und ihre Beziehung zur Arteriosklerose. Beitr. path. Anat.38, 229–254 (1905).Google Scholar
  164. 165.
    Wexler, B. C., Serum creatine phosphokinase activity following isoproterenol-induced myocardial infarction in male and female rats with and without arteriosclerosis. Amer. Heart. J.79, 69–79 (1970).PubMedGoogle Scholar
  165. 166.
    Wexler, B. C., J. T. Judd, andG. W. Kittinger, Myocardial necrosis induced by isoproterenol in rats: Changes in serum protein, lipoproteinlipids and glucose during acitive necrosis and repair in arterosclerotic and non-arterosclerotic animals. Angiology19, 665–682 (1968).Google Scholar
  166. 167.
    Wexler, B. C., G. W. Kittinger, andJ. T. Ludd, Divergent responses to drug-induced myocardial infarction between rats having varying degress of arterosclerosis. Circulat. Res.20, 78–87 (1967).PubMedGoogle Scholar
  167. 168.
    Werler, B. C. andG. W. Kittinger, Myocardial necrosis in rats: serum enzymes, adrenal steroid and histopathological alterations. Circulat. Res.13, 159 (1963).Google Scholar
  168. 169.
    Wexler, B. C. andG. W. Kittinger, Steroids produced in vitro by adrenal glands of normal and arteriosclerotic rats during and after drug-induced myocardial necrosis. Circulat. Res.16, 322–331 (1965).PubMedGoogle Scholar
  169. 170.
    Wroblewski, F. andJ. S. La Due, Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. (N.Y.)90, 210–213 (1955).Google Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag 1973

Authors and Affiliations

  • E. Marmo
    • 1
  • A. P. Caputi
    • 1
  • R. K. Saini
    • 1
  1. 1.Department of Pharmacology and ToxicologyUniversity of Naples(Italy)

Personalised recommendations